Note from Dr. Janet Dancey, Scientific Director, 3CTN
RE: Coordinating Centre Staff Update
Dear Colleagues,
As some of you may know, Karen Arts has been managing some health-related issues and as a result will be going on long-term medical leave starting February 1, 2018.
We as a clinical trial community have benefited from her vision, and unfailing efforts to improve the clinical research environment in Ontario and across Canada in her roles as Executive Director of the Canadian Cancer Clinical Trials Network (3CTN) and as Chair and Co-founder of N2. In addition, she has contributed to many collaborative efforts with stakeholders internationally. All of us who have been privileged to work with her will miss her passionate commitment and leadership. I am sure I speak for all in thanking her for her commitment and in wishing her well.
Karen will continue to guide 3CTN until her leave commences at the end of the month. We are starting a talent search to fill Karen’s position during her leave and will provide updates in the coming weeks. Starting February 1, for the interim period, please contact Diana Kato in Karen’s absence.
Janet
Janet Dancey, MD, FRCPC
Scientific Director, Canadian Cancer Clinical Trials Network
Director, Canadian Cancer Trials Group
Job Opportunities
3CTN currently has two positions available. For more information and to apply, visit the links below.
